PRESECO clinical trial for Avigan : Appili begins dosing in phase 3 Covid-19 study
Appili Therapeutics said that it has dosed the first participant in the phase 3 PRESECO clinical trial for Avigan tablets (favipiravir) for the oral treatment ... Read More